Gene-Specific Treatment Advancing Antisense Oligonucleotides Market

According to FutureWise analysis the market for antisense oligonucleotides in 2023 is US$ 2.12 billion, and is expected to reach US$ 4.73 billion by 2031 at a CAGR of 10.50%.

Antisense oligonucleotides (ASOs), also known as AONs, are small molecules designed to influence the production of proteins within cells. These ASOs are composed of short, single-stranded DNA fragments that have sequences complementary to specific messenger RNA (mRNA) molecules. Proteins are vital for numerous cellular functions and are synthesized through a two-step process: first, a gene encoding a protein is transcribed into mRNA, which acts as a blueprint carrying genetic instructions. This mRNA is then translated into the respective protein in the cellular machinery responsible for protein synthesis. Additionally, ASOs can engage cellular mechanisms that lead to the degradation of the targeted mRNA, further inhibiting the synthesis of the corresponding protein.

ASOs have a wide range of therapeutic applications across various diseases, including ocular disorders, cancer, diabetes, and Amyotrophic Lateral Sclerosis (ALS), among others. In ocular medicine, ASOs can be tailored to target specific genetic mutations linked to inherited retinal disorders or other eye conditions. In oncology, they focus on genes or gene products that play a role in the growth and progression of tumors. Furthermore, ASOs are being investigated for their potential to treat diabetes, particularly in instances where genetic factors influence the disease. They are designed to target genes involved in insulin production, sensitivity, or other aspects related to glucose metabolism.

FutureWise Market Research has published a report that provides an insightful analysis of Antisense Oligonucleotides Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=13413&type=requestsample

Antisense Oligonucleotides Market Segmentation:

By Drug

• Approved Drugs
  • Pegaptanib
  • Mipomersen
  • Eteplirsen
• Pipeline Analysis

By Indication

• Ocular Diseases
• Cancer
• Diabetes
• Amyotrophic Lateral Sclerosis (ALS)
• Duchenne Muscular Dystrophy
• Spinal Muscular Atrophy
• Others

By Application

• Basic Research
• Genomics
• Target Validation
• Drug Discovery

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Antisense Oligonucleotides Market:

• Aesthetic Experts Lab
• Aptos International Ltd.
• Croma Pharma GmbH.
• Healux Corporation
• Menarini Group
• Metro Korea Co., Ltd.
• N-Finders Co., Ltd.
• Medical Aesthetic Group
• Sinclair Pharma PLC.
• Spring Thread (1st Surgiconcept)
• V Soft Lift AB
• Modern Aesthetics
• Intraline

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=13413&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Antisense Oligonucleotides Market By Product Type, By Application and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/76182-Gene-Specific-Treatment-Advancing-Antisense-Oligonucleotides-Market.html